Floatz logo

Solu-Cortef

Duodenal Carcinoma

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Phase 4 / ApprovedActive
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Duodenal Carcinoma cohort.

Asset / SponsorPhaseRating
Octreotide Pamoate
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 4BB
Obeticholic Acid
National Cancer Institute (NCI)
Phase 2CCC
URSODEOXYCHOLIC ACID
National Cancer Institute (NCI)
Phase 2CCC

Same molecule, other indications

Solu-Cortef is also rated in:

congenital adrenal hyperplasiaDormant
A
Indicative ·
81 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →